Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation.

ABSTRACT:

SUBMITTER: Hanf D 

PROVIDER: S-EPMC8232550 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature